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Abstract. – OBJECTIVE: The incidence of ab-
normal cervical cytology in pregnancy is similar
to that reported for non-pregnant women. Fur-
thermore, 1% of pregnant women annually
screened for cervical cancer will be diagnosed
with cervical intraepithelial neoplasia (CIN) of
various degrees. For this reason, Pap smear
should be performed in the first trimester of
pregnancy. The persistence of HR-HPV infec-
tion is related to the development of CIN. How-
ever, the relationship between CIN and HR-HPV
infection during pregnancy and postpartum can
hardly be found. The aim of this work was to as-
sess the proper management of abnormal cytol-
ogy during and after pregnancy evaluating re-
gression rate, persistence rate and risk of pro-
gression and the predictive role of HPV molecu-
lar tests.
PATIENTS AND METHODS: Patients with ab-
normal cervical cytology were followed-up using
colposcopy and colposcopy-directed biopsies
every 12 weeks. Molecular tests were performed
at the moment of the cytological diagnosis. Pa-
tients not treated in pregnancy were re-evaluat-
ed with cytology, colposcopy, biopsies, HPV-
DNA test and HPV-mRNA test for a final diagno-
sis 8 weeks postpartum. Women with a persis-
tent CIN 2-3 lesion at this follow-up check, un-
derwent an excisional procedure by LEEP and
then re-evaluated every 6 months for a year.
RESULTS: HPV-DNA test showed a sensitivity
of 90.5% and a negative predictive value of
96.4%. Specificity and positive predictive values
were 67.9% and 43.2%, respectively. For HPV-
mRNA test, a sensitivity of 76.2% and a NPV of
93.9% were found; specificity and PPV were
98.7% and 94.1% respectively.
CONCLUSIONS: An observational manage-
ment based on the use of molecular test and
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particularly HPV-mRNA test for its higher speci-
ficity, is a reasonable possibility in the follow-up
of CIN2/3 lesions during pregnancy.
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Introduction
Cervical cancer is the most common gyneco-
logic neoplasia encountered during pregnancy,
with an incidence ranging from 1.6 to 10.6/10
000 pregnancies. Approximately 30% of women
diagnosed with cervical cancer is in the repro-
ductive age, and an overall 3% of cases is diag-
nosed in pregnancy1. The occurrence of abnor-
mal cervical cytology in pregnancy is similar to
that reported for non-pregnant women (5-8%)2;
however, the majority of pregnancies occurs in
the age range 18-25, that is also the age range as-
sociated with the higher prevalence of cervical
intraepithelial neoplasia, estimated to be 0.08-
5.0%3,4. For a long time, pregnancy was consid-
ered as a condition at higher risk of complica-
tions, such as heavy bleeding, infections, and
miscarriage, discouraging any procedure to be
performed on the uterine cervix5.
The identification of HPV as causa sine qua
non for the onset of CIN, and consequently of in-
vasive cervical cancer, has promoted the devel-
opment of some molecular tests, aimed to reveal
the presence of cervical HPV infection and the
oncogenic activity of the virus. HPV-mRNA test
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is a progression index, indicating the persistent
expression of viral proteins that are integrated in-
to the cellular genome and responsible for the
cellular transformation. HPV-DNA test is a risk
parameter because the presence of the virus caus-
es a 100-folds increase of the risk of developing
a preneoplastic or neoplastic lesion6.
Some studies have shown that persistent HR-
HPV infection is closely related to CIN occur-
rence and development. In a recent one, He et al7
evaluated the role of HPV-DNA test in pregnant
women with abnormal Pap smear, reporting two
interesting results: during pregnancy as the CIN
grade increased, the HR-HPV infection rates in-
creased (p = 0.002), while 3-6 months postpar-
tum as the CIN grade increased, the natural nega-
tive rate of HR-HPV decreased (p = 0.000). The
aim of this study was to assess the proper man-
agement of low and high squamous intraepithe-
lial lesion (LSILs and HSILs) during and after
pregnancy evaluating regression rate, persistence
rate and risk of progression and the predictive
role of HPV molecular tests.
Patients and Methods
From January 2009 to December 2014, 500
pregnant women attended at the Department of
Surgical and Medical Science and Translational
Medicine, Faculty of Medicine and Psychology,
Sapienza University of Rome and to Section of
Gynecology and Obstetrics, Department of Sur-
gical Sciences, Tor Vergata University Hospital,
Rome. All patients recruited were properly eluci-
dated and signed an informed consent (Prot. CE
1591/13). The study was conducted in accor-
dance to the Helsinki Declaration. Patients, who
had not received a Pap smear for more than one
year, were submitted to cervical cytological
screening. Cytological findings were reported in
agreement with the 2001 Bethesda Reporting
System8. Patients with low and high squamous
intraepithelial lesions (LSIL, HSIL) were evalu-
ated with colposcopy. A standard OM50 Zeiss
colposcope (Carl Zeiss, Inc., Oberkochen, Ger-
many) was used and the examination was per-
formed after the application of a 5% acetic acid
solution, followed by a Schiller test. Colposcopy
was considered satisfactory when the squamous-
columnar junction (SCJ) was entirely detected.
Colposcopic findings were formulated according
to the International Nomenclature IFCPC 20129.
In the areas showing the higher grade of atypia,
colposcopy-directed biopsies were executed. The
excised specimens were fixed with a 10% forma-
lin solution and microscopically examined. In or-
der to assess the most frequently represented
HPV genotype, the DNA genotyping was per-
formed with the LiPA (Innogenetics, Gent, Bel-
gium) using biotinylated SPF10 PCR primers for
the amplification of a 65-bpregion of the L1 gene
of a broad spectrum of HPV types (AmpliTaq
Gold DNA polymerase; Applied Biosystems,
Foster City, CA, USA). LiPA is capable of de-
tecting 26 HPV types: HR-HPV genotypes 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68,
and 70; low-risk HPV genotypes 6, 11, 34, 40,
42, 43, 44, 53, 54, and 74. The assay was per-
formed according to the manufacturer’s protocol.
HPV-DNA test was performed using Hybrid
Capture 2 (HC2 Digene Corporation, Gaithers-
burg, MD, USA), that is a semi-quantitative sig-
nal-amplified hybridization assay for the chemi-
luminescent detection of the 13 most common
HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, and 68). Digene Hybrid CaptureII
hybridization assay (HC2 Digene Corporation,
Gaithersburg, MD, USA) was performed in
agreement with the manufacturer’s instructions.
The PreTect HPV-Proofer Kit (referred to as the
mRNA test) (Norchip, Klokkarstua, Norway)
was used for the detection of E6/E7 mRNA of
HPV types16, 18, 31, 33 and 45, according to the
manufacturer’s instructions. Five milliliters of
PreservCyt sample were processed for the extrac-
tion of HPV-mRNA using the RNeasy Mini Kit
(QIAGEN, Milan, Italy). The PreTect HPV-
Proofer utilizes an isothermal nucleic acid se-
quence-based amplification (NASBA), which
amplifies mRNA in a DNA background, detect-
ing and genotyping HPV transcripts in the same
reaction. The amplified products were detected
in real time using fluorescent-labelled molecular
beacon probes directed against full-length E6/E7
mRNA. Accumulated mRNA fluorescent pro-
files were analyzed and assigned a positive or
negative status, for each type included, by the
supplied PreTect analysis software. During preg-
nancy, patients with abnormal cervical cytology
were followed up using colposcopy and, if neces-
sary, colposcopy-directed biopsies every 12
weeks. Furthermore, molecular tests were per-
formed at the moment of the cytological diagno-
sis. Women with cytological HSIL and colpo-
scopic abnormalities suggestive of microinvasion
or cytological HSIL with endocervical involve-
ment were submitted to an excisional procedure
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Figure 1. Flow-chart.
by LEEP, within 16-18 weeks of pregnancy. These
patients were excluded from the study. Patients not
treated in pregnancy were reevaluated with cytol-
ogy, colposcopy, biopsies, HPV-DNA test and
HPV-mRNA test for a final diagnosis 8 weeks af-
ter delivery. Those women, who showed a persis-
tent CIN 2-3 lesion at this follow-up check, were
submitted to an excisional procedure by LEEP and
then re-evaluated every 6 months for a year.
Statistical Analysis
The collected data were analyzed using the
statistical package SPSS (v. 21) and MedCalc (v.
15.2.1), the latter of which is specifically dedi-
cated to the processing of biomedical data. More-
over, sensitivity, specificity, negative predictive
value (NPV) and positive predictive value (PPV)
have been calculated to assess the accuracy of
both molecular tests, HPV-DNA and HPV-mR-
NA test. The significance level was set at 0.05
(p-value, Sig < 0.05).
Results
Out of 500 pregnant patients screened with
cervical smear, 116 reported a cytological diag-
nosis of squamous intraepithelial lesions. Two
patients were lost after the first prenatal check,
six were lost after delivery, and four were lost af-
ter the first postpartum check, so that the final
study population was composed of 104 patients
(Figure 1). The clinical characteristics of the
study population are summarized in Table I.
The genotyping showed that HPV-16 was
most commonly detected (65.4%). HPV-18 was
the second most common type (15.6%). Other
common genotypes detected were HPV-33
(12%) and HPV-31 (7%).
During pregnancy, the HR-HPV-DNA test
was positive in 73/99 (73.7%) cases, of whom 26
(61.9%) CIN 1, 22 (73.3%) CIN 2 and 25
(92.6%) CIN 3. On the contrary, the test was
negative in 16 (38.1%) CIN 1, 8 (26.7%) CIN 2
and 2 (7.4%) CIN 3.
At the 8 weeks postpartum check, the HPV-
DNA test was negative in 29/73 (39.7%) cases:
particularly, it was negative in 15 (61.5%) out of
26 CIN 1 cases, in 11 (50%) out of 22 CIN 2 cas-
es and in 3 (12%) out of 25 CIN 3 cases.
During pregnancy, the HPV-mRNA test was
positive for HR-HPV in 43/99 cases (43.4%), of
whom 17 (40.5%) CIN 1, 13 (43.3%) CIN 2 and
13 CIN 3 (48.1%); on the contrary, it was nega-
tive in 25 (59.5%) CIN 1, 17 (56.7%) CIN 2 and
14 CIN 3 (51.9%).
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At the 8 weeks postpartum check, the HPV-
mRNA test resulted negative in 26/43 (60.5%)
cases: in particular, it was negative in 11 (64.7%)
out of 17 cases of CIN 1, in 8 (61.5%) out of 13
CIN 2 and in 7 (53.8%) out of 12 CIN 3 (Tables
II and III).
The accuracy of both molecular tests was also
assessed. For HPV-DNA test, a sensitivity of
90.5% (95% CI, 0.7-1) was found and a negative
predictive value (NPV) of 96.4% (95% CI, 0.9-
1). Moreover, specificity and positive predictive
value (PPV) were 67.9% (95% CI, 0.6-0.8) and
43.2% (95% CI, 0.3-0.6), respectively. As regard
to HPV-mRNA test, a sensitivity of 76.2% (95%
CI, 0.6-0.9) and a NPV of 93.9% (95% CI, 0.7-1)
were found; specificity and PPV were 98.7%
(95% CI, 0.9-1) and 94.1% (95% CI, 0.7-0.9), re-
spectively.
Patients diagnosed with high-grade dysplasia
at the 8 weeks postpartum check (one CIN 1 pro-
gressed to CIN 2, 5 persistent CIN 2, 1 CIN 3 re-
gressed to CIN 2, 8 persistent CIN 3) were sub-
mitted to an excisional procedure by LEEP. Pa-
tients with low-grade dysplasia (four persistent
CIN 1, 2 CIN 2 regressed to CIN 1) were fol-
lowed-up. All the study population (99 pts) was
reevaluated every 6 months for a year using cy-
tology, colposcopy, histology and molecular
tests.
Six months after LEEP, Pap test resulted posi-
tive in 17 (17.2%) out of 99 patients: 4 (23.5%)
LSIL and 13 (76.5%) HSIL. At the colposcopic
examination, 4 (23.5%) ANTZ resulted in grade
I of abnormality and 13 (76.5%) ANTZ were
grade II. The histologic analysis revealed the fol-
lowing results: 4 (23.5%) CIN 1, 7 (41.2%) CIN
2 and 6 (35.3%) CIN 3. The remaining 82
(82.8%) patients reported negative cytocolpo-
scopic and histologic results.
Clinical characteristics
Mean gestational age at diagnosis 10 weeks
Meanage 27 years (21-37)
Mean parity 1.7 (0-4)
Mean age at first sexual intercourse 18 years (14-27)
Mean number of sexual partners 4 (1-8)
Tobacco use (current or past) 34.3%
Mean BMI 25.3 (20-31)
Table I. Clinical characteristics of the study population.
HR-HPV DNA test HR-HPV mRNA test
Pregnancy 8 weeks postpartum Pregnancy 8 weeks postpartum
Positive Negative Positive Negative Positive Negative Positive Negative
CIN 1 26 (61.9%) 16 (38.1%) 11/26 (42.3%) 15/26 (61.5%) 17 (40.5%) 25 (59.5%) 6/17 (35.3%) 11/17 (64.7%)
CIN 2 22 (73.3%) 8 (26.7%) 11/22 (50%) 11/22 (50%) 13 (43.3%) 17 (56.7%) 5/13 (38.5%) 8/13 (61.5%)
CIN 3 25 (92.6%) 2 (7.4%) 22/25 (88%) 3/25 (12%) 13 (48.1%) 14 (51.9%) 6/13 (46.2%) 7/12 (53.8%)
Total 73 (73.7%) 26 (26.3%) 44 (60.3%) 29 (39.7%) 43 (43.4%) 57 (56%) 17 (39.5%) 26 (60.5%)
Table II. HPV-DNA test and mRNA test results in pregnancy and 8 weeks postpartum. Number of patients (%).
HPV-DNA test HPV-mRNA test
Positive Negative Positive Negative
8 weeks postpartum histology n (%) n (%) n (%) n (%)
CIN 1 Regressed to normal 37 (88.1%) 6 (14.3%) 31 (73.8%) 1 (2.4%) 36 (85.7%)
Persistent/progressed dysplasia 5 (11.9%) 5 (11.9%) 0 (0%) 5 (11.9%) 0 (%)
CIN 2 Regressed to normal 23 (76.7%) 6 (20%) 17 (56.7%) 0 (0%) 23 (76.7%)
Persistent/progressed dysplasia 7 (23.3%) 5 (16.7%) 2 (6.6%) 5 (16.7%) 2 (6.6%)
CIN 3 Regressed to normal 18 (66.7%) 13 (48.1%) 5 (18.6%) 0 (0%) 18 (66.7%)
Persistent/progressed dysplasia 9 (33.3%) 9 (33.3%) 0 (0%) 6 (22.2%) 3 (11.1%)
Table III. Results of HPV-DNA test and HPV-mRNA test in relationship to histological findings at 8 weeks postpartum.
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Both molecular tests were repeated in all the
study population (99 pts). The HPV-DNA test
was positive in 27 (27.3%) out of 99 cases, of
whom 6 (14.3%) out of 42 CIN 1, 8 (26.7%) out
of 30 CIN 2 and 13 (48.1%) out of 27 CIN 3.
The HPV-mRNA test resulted positive in 14/99
(12.8%) cases: in particular, it was positive in 4
(9.5%) out of 42 CIN 1, 5 (16.7%) out of 30 CIN
2 and 5 (22.2%) out of 27 CIN 3.
One year after LEEP, Pap test was positive in
11 (11.1%) out of 99 patients: 2 (18.2%) LSIL and
9 (81.8%) HSIL. At the colposcopic examination,
2 (18.2%) ANTZ resulted in grade I of abnormali-
ty and 9 (81.8%) ANTZ were grade II. The histo-
logic analysis revealed the following results: 2
(18.2%) CIN 1, 5 (45.4%) CIN 2 and 4 (36.4%)
CIN 3. The remaining 88 (88.9%) patients report-
ed negative cytocolposcopic and histologic results.
All the study population (99 pts) was reevalu-
ated using both molecular tests. The HPV-DNA
test was positive in 18 (18.2%) out of 99 cases,
of whom 3 (7.1%) out of 42 CIN 1, 5 (16.7%)
out of 30 CIN 2 and 10 (37.0%) out of 27 CIN 3.
The HPV-mRNA test resulted positive in 9/99
(9.1%) cases: in particular, it was positive in 2
(4.8%) out of 42 CIN 1, 3 (10%) out of 30 CIN 2
and 4(14.8%) out of 27 CIN 3.
Discussion
All pregnant women, in the absence of a re-
cent Pap smear, should be submitted to a cyto-
logical screening examination10. Pap smear
should be performed in the first trimester of
pregnancy10. However, in the interpretation of
Pap smear during pregnancy, physicians should
be aware of the physiologic pregnancy-related
cellular changes that could mimic the cytological
appearance of a high-grade SIL and cause a false
positive diagnosis: degenerated decidual cells
(Arias-Stella reaction) and trophoblastic cells
with variable cytoplasmic staining and enlarged
nuclei11. Also, the colposcopic examination
could be more difficult due to the pregnancy: the
active immature metaplasia can create a large
thin aceto-white areas, with fine punctuation or
mosaicism that could mimic a low-grade intraep-
ithelial lesion5. The late stromal decidualization
may appear as dense acetowhite lesions with spi-
dery superficial blood vessels that appear similar
to a high-grade lesion; a thin ring of decidualized
aceto-white stroma may surround normal capil-
laries, causing a “starry-sky” appearance12.
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The main purpose of colposcopy in pregnancy
is to exclude invasive disease2: only the colpo-
scopic impression of invasive cancer requires a
more accurate evaluation and a prompt decision
making, while the management of preinvasive le-
sions may be conservative and treatment can be
safely postponed until the postpartum period13.
If at colposcopy a high-grade lesion is seen or
suspected, targeted biopsies should be per-
formed. Despite the increased vascularization of
the cervix, cervical biopsy in pregnancy is a safe
procedure, with a hemorrhage risk of only 0.6%,
which is similar to that reported in non-pregnant
women10.
Based on the 2006 guidelines of the American
Society of Colposcopy and Cervical Pathology
(ASCCP) in pregnant women with ASC variant
or LSIL cytology, colposcopy and subsequent
management could be postponed until 6 weeks
postpartum, because these abnormalities are like-
ly to regress spontaneously with expectant man-
agement and unlikely to harbor an invasive oc-
cult neoplasia13. Indeed, Fader et al13 reported a
postpartum regression of 86% of low-grade le-
sions with no cases of invasive cancer. More-
over, pregnant women with ASC-US or LSIL cy-
tology rarely have a colposcopic impression of
CIN 2-3 at their initial colposcopy14.
In pregnant patients diagnosed with HSIL cy-
tology, the ASCCP guidelines support that cervi-
cal biopsies and serial colposcopies during preg-
nancy are acceptable if the colposcopic impres-
sion is CIN 2-3 or invasive cancer. However,
Fader et al13 suggest that biopsies and repeated
colposcopies may not be necessary during preg-
nancy if the colposcopic impression is of CIN 2-
3, as these lesions are unlikely to progress and
likely to regress during or within the first year af-
ter pregnancy (35%), with a low risk of invasive
malignancy (0.45-1/1000 live births). However,
in women with previously untreated cervical dys-
plasia or with risk factors for persistent or pro-
gressive disease (such as smoking or immuno-
suppression) or noncompliance, antepartum cer-
vical biopsies and serial colposcopies are reason-
able.
The use of molecular test (HPV-DNA and
HPV-mRNA test) is well known in the manage-
ment of HPV infections. Dockter et al15 showed
in their study how HPV-mRNA (APTIMA) had
a similar sensitivity to the HC2 test for detection
of CIN2+ and CIN3+ but the clinical specificity
of APTIMA HPV assay for detection of CIN2+
and CIN3+ was significantly higher than that of
the HC2 test. Our results, concerning the accura-
cy of both molecular testing the detection of
CIN2/3 lesions in pregnant women, are in agree-
ment with previously mentioned study (HPV
DNA: sensibility 90.5% and specificity 67.9%;
HPV mRNA: sensibility 76.2% and specificity
98.7%) so, in this regard, pregnancy does not
seem to influence HPV detection16.
Compared to the HPV DNA test, the higher
specificity and the lower sensibility of HPV mR-
NA test could be explained by the limited num-
ber of genotypes targeted by the mRNA test17.
Moreover, CIN2-3 lesions linked with those
oncogenic types not targeted by Proofer will
regress spontaneously18. The HPV-mRNA test
was not positive in all patients who experienced
a recurrent disease. Finally, during pregnancy
HPV-mRNA test designed to detect transcrip-
tionally active infection with the five most com-
mon oncogenic HPV types (16, 18, 31, 33 and
45) might still identify the majority of women
whose lesions are likely to progress.
Conclusions
An observational management based on the
use of molecular test and particularly HPV-mR-
NA test for its higher specificity is a reasonable
possibility in the follow-up of CIN2/3 lesions
during pregnancy. HPV mRNA test may be con-
sidered as a tool in risk stratification. Moreover,
the management of preinvasive lesions should be
observational, looking for the balance between
the risk of progression of the disease and the
overtreatment that could set negatively the preg-
nancy outcomes.
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